scholarly journals In vivo multiphoton imaging of an ovarian cancer mouse model

2019 ◽  
Author(s):  
Travis W. Sawyer ◽  
Photini F. Rice ◽  
Jennifer W. Koevary ◽  
Jennifer K. Barton ◽  
Denise C. Connolly ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Multiphoton Imaging

scholarly journals In vivo optical coherence tomography of a mouse model of spontaneous ovarian cancer

2019 ◽  
Author(s):  
Travis W. Sawyer ◽  
Jennifer Watson-Koevary ◽  
Photini F. S. Rice ◽  
Jennifer K. Barton
Keyword(s):  
Ovarian Cancer ◽  
Optical Coherence Tomography ◽  
Mouse Model ◽  
Optical Coherence

scholarly journals In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

2011 ◽  
Vol 10 (8) ◽  
pp. 1440-1449 ◽  
Author(s):  
Kathryn M. Kinross ◽  
Daniel V. Brown ◽  
Margarete Kleinschmidt ◽  
Susan Jackson ◽  
James Christensen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Mek Inhibition ◽  
Pten Deletion

scholarly journals A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Mitchell Clark ◽  
Alexandra Kollara ◽  
Theodore J. Brown ◽  
Taymaa May
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mouse Model ◽  
Cytoreductive Surgery ◽  
Residual Disease ◽  
Accelerated Expansion ◽  
Ovarian Cancer Cells ◽  
Orthotopic Mouse Model ◽  
The Impact

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.

Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance

2020 ◽  
Vol 20 (1) ◽  
pp. 85-95
Author(s):  
Zhiqing Huang ◽  
Eiji Kondoh ◽  
Zachary R. Visco ◽  
Tsukasa Baba ◽  
Noriomi Matsumura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Platinum Resistance

Abstract 5259: Non-invasive determination of in vivo myeloperoxidase activity in ovarian cancer mouse model

2012 ◽  
Author(s):  
Rao V. Papineni ◽  
Vinicius Craveiro ◽  
John Pizzonia ◽  
Jennie Holmberg ◽  
Gil Mor
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Myeloperoxidase Activity ◽  
Non Invasive
Sign in / Sign up

Export Citation Format

Share Document